Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

MISSION Therapeutics Strengthens Board

Published: Monday, October 01, 2012
Last Updated: Monday, October 01, 2012
Bookmark and Share
Appointments of Michael Moore and Fritz Frickel as Executive Chairman and Non-Executive Director respectively.

MISSION Therapeutics has announced the appointment of Dr Michael Moore as Executive Chairman and Fritz Frickel as Non-Executive Director.

Graziano Seghezzi of Sofinnova partners, on behalf of the investor syndicate, commented: “We warmly welcome Michael Moore and Fritz Frickel to the MISSION Board. Their combined commercial, drug translational and managerial experience will complement our existing capabilities and provide valuable links with the pharma and venture capital industries with which they have both enjoyed highly productive relationships”.

Dr Moore brings extensive experience to MISSION at a formative phase of the company’s development.

Following an earlier academic career principally at the Paterson Institute for Cancer Research (University of Manchester), Dr Moore has more than two decades of senior management experience in the biotechnology sector, as Chief Scientific Officer of Xenova Group plc and more recently as Chief Executive Officer of Piramed, the UK bioscience company acquired by F Hoffmann-La Roche in 2008.

Dr Moore also serves as a Non-Executive Director of several companies including PsiOxus Therapeutics. He is also a member of the Cancer Research UK Science Committee.

Dr Fritz Frickel joins the MISSION Board as a non-executive director. Currently an independent advisor to venture capital firms, biotech start-ups and universities, Dr Frickel was formerly Senior Vice-President of R&D and acting CEO of Alantos which was acquired by Amgen.

Other senior pharma roles have included SVP of research at Abbott, world-wide head of research at BASF and head of clinical, pharmaceutical and regulatory development at Knoll.

Dr Frickel served as non-executive director of RespiVert, an Imperial College spin-out, until its acquisition by Janssen Biotech Inc. in 2010 and is currently a director of new start-up company TopiVert.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MISSION Secures £20 million ($32 million) in Series B Financing
Pfizer Venture Investments join MISSION investor syndicate to advance compounds through preclinical development for genetically-defined cancers.
Tuesday, November 19, 2013
Biomedical Catalyst Feasibility Award to Tackle Drug-resistant Ovarian Cancer
Feasibility award granted by Technology Strategy Board to identify DUBs.
Tuesday, September 17, 2013
Appointment of Associate Faculty Member at Sanger Institute
MISSION Co-Founder and CSO, Professor Steve Jackson appointed as Faculty Member.
Monday, April 08, 2013
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos